Raltitrexed (Tomudex) concomitant with radiotherapy as adjuvant treatment for patients with rectal cancer: preliminary results of phase I studies.

2.50
Hdl Handle:
http://hdl.handle.net/10541/88030
Title:
Raltitrexed (Tomudex) concomitant with radiotherapy as adjuvant treatment for patients with rectal cancer: preliminary results of phase I studies.
Authors:
James, Roger D; Price, Patricia M; Valentini, V
Abstract:
Radiotherapy, either alone or in combination with chemotherapy, may reduce local recurrence of rectal cancer following surgery and improve survival of patients with operable and advanced/recurrent/inoperable disease. Chemotherapy with 5-fluorouracil in combination with radiotherapy has been used both before and after surgery; however, the optimum schedule is unclear. In addition, alternative chemotherapy with raltitrexed (Tomudex) may be more convenient and better tolerated. The preliminary results of three phase I dose-finding studies are described, combining escalating doses of raltitrexed with radiotherapy as pre- or postoperative treatment for operable rectal cancer or as treatment for advanced/inoperable/recurrent rectal cancer. The recommended dose of raltitrexed when combined with adjuvant radiotherapy is likely to be 2.6 mg/m2. This is a small dose reduction compared with the dose of raltitrexed for the treatment of advanced colorectal cancer (3.0 mg/m2); however, toxicity appears to be lower using the pre-operative approach. Neo-adjuvant therapy with raltitrexed plus radiotherapy also demonstrated clinical activity in the pre-operative study, which showed that 22% of patients achieved a complete response and 56% a partial response. Once the recommended dose has been defined in each setting, large-scale studies will be undertaken as appropriate.
Affiliation:
Department of Clinical Oncology, Christie Hospital, Manchester, U.K.
Citation:
Raltitrexed (Tomudex) concomitant with radiotherapy as adjuvant treatment for patients with rectal cancer: preliminary results of phase I studies. 1999, 35 Suppl 1:S19-22 Eur. J. Cancer
Journal:
European Journal of Cancer
Issue Date:
Mar-1999
URI:
http://hdl.handle.net/10541/88030
DOI:
10.1016/S0959-8049(99)00044-1
PubMed ID:
10645210
Type:
Article
Language:
en
ISSN:
0959-8049
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorJames, Roger Den
dc.contributor.authorPrice, Patricia Men
dc.contributor.authorValentini, Ven
dc.date.accessioned2009-12-15T16:08:13Z-
dc.date.available2009-12-15T16:08:13Z-
dc.date.issued1999-03-
dc.identifier.citationRaltitrexed (Tomudex) concomitant with radiotherapy as adjuvant treatment for patients with rectal cancer: preliminary results of phase I studies. 1999, 35 Suppl 1:S19-22 Eur. J. Canceren
dc.identifier.issn0959-8049-
dc.identifier.pmid10645210-
dc.identifier.doi10.1016/S0959-8049(99)00044-1-
dc.identifier.urihttp://hdl.handle.net/10541/88030-
dc.description.abstractRadiotherapy, either alone or in combination with chemotherapy, may reduce local recurrence of rectal cancer following surgery and improve survival of patients with operable and advanced/recurrent/inoperable disease. Chemotherapy with 5-fluorouracil in combination with radiotherapy has been used both before and after surgery; however, the optimum schedule is unclear. In addition, alternative chemotherapy with raltitrexed (Tomudex) may be more convenient and better tolerated. The preliminary results of three phase I dose-finding studies are described, combining escalating doses of raltitrexed with radiotherapy as pre- or postoperative treatment for operable rectal cancer or as treatment for advanced/inoperable/recurrent rectal cancer. The recommended dose of raltitrexed when combined with adjuvant radiotherapy is likely to be 2.6 mg/m2. This is a small dose reduction compared with the dose of raltitrexed for the treatment of advanced colorectal cancer (3.0 mg/m2); however, toxicity appears to be lower using the pre-operative approach. Neo-adjuvant therapy with raltitrexed plus radiotherapy also demonstrated clinical activity in the pre-operative study, which showed that 22% of patients achieved a complete response and 56% a partial response. Once the recommended dose has been defined in each setting, large-scale studies will be undertaken as appropriate.en
dc.language.isoenen
dc.subjectRectal Canceren
dc.subject.meshAged-
dc.subject.meshAntimetabolites, Antineoplastic-
dc.subject.meshChemotherapy, Adjuvant-
dc.subject.meshDose-Response Relationship, Drug-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshMale-
dc.subject.meshMiddle Aged-
dc.subject.meshQuinazolines-
dc.subject.meshRadiotherapy, Adjuvant-
dc.subject.meshRectal Neoplasms-
dc.subject.meshThiophenes-
dc.subject.meshTreatment Outcome-
dc.titleRaltitrexed (Tomudex) concomitant with radiotherapy as adjuvant treatment for patients with rectal cancer: preliminary results of phase I studies.en
dc.typeArticleen
dc.contributor.departmentDepartment of Clinical Oncology, Christie Hospital, Manchester, U.K.en
dc.identifier.journalEuropean Journal of Canceren

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.